Renaissance Capital LLC Boosts Position in Kenvue Inc. (NYSE:KVUE)

Renaissance Capital LLC increased its stake in Kenvue Inc. (NYSE:KVUE) by 9.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 723,592 shares of the company’s stock after acquiring an additional 61,330 shares during the quarter. Kenvue accounts for approximately 10.1% of Renaissance Capital LLC’s portfolio, making the stock its largest position. Renaissance Capital LLC’s holdings in Kenvue were worth $15,449,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. Grove Bank & Trust increased its position in shares of Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after acquiring an additional 947 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in Kenvue during the 4th quarter worth approximately $29,000. Riverview Trust Co bought a new position in shares of Kenvue in the third quarter valued at approximately $30,000. Fortitude Family Office LLC boosted its position in shares of Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after buying an additional 777 shares during the last quarter. Finally, Ashton Thomas Securities LLC bought a new stake in Kenvue during the third quarter worth $35,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Down 0.3 %

KVUE stock opened at $21.22 on Tuesday. The stock has a fifty day moving average of $21.90 and a 200-day moving average of $21.92. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The company has a market capitalization of $40.69 billion, a price-to-earnings ratio of 38.59, a PEG ratio of 2.05 and a beta of 1.45. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.01. The firm had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company’s revenue was down .4% on a year-over-year basis. During the same quarter last year, the company earned $0.31 earnings per share. As a group, equities research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.86%. Kenvue’s dividend payout ratio (DPR) is 149.09%.

Analyst Upgrades and Downgrades

KVUE has been the topic of several recent analyst reports. JPMorgan Chase & Co. raised their price objective on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. UBS Group cut their price target on shares of Kenvue from $24.00 to $23.00 and set a “neutral” rating on the stock in a report on Thursday, January 16th. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and decreased their price objective for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Bank of America upped their target price on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. Finally, Citigroup dropped their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.